Company: RPTX
Filing Date: 2025-11-17
Form Type: 8-K
Source: 0001193125-25-284035
Chunk: 0

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement.  

Arrangement Agreement

On November 14, 2025, Repare Therapeutics Inc. (the “ Company”) entered into an Arrangement Agreement (the “ Agreement”) with XenoTherapeutics, Inc., a Massachusetts non-profitcorporation (“ Xeno”), Xeno Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Xeno (“ Purchaser”), and solely for purposes of Section 9.15 thereof, XOMA Royalty Corporation, a Nevada corporation (“ XRC”), pursuant to which Purchaser will acquire all of the issued and outstanding common shares (the “ Common Shares,” and the holders of such Common Shares, the “ Shareholders”) of the Company (the “ Transaction”). Under the terms of the Agreement, the Shareholders will receive a cash payment per Common Share (the “ Cash Amount”) that will be determined based upon the Company’s cash balance immediately prior to the closing of the Transaction (“ Closing”) after deducting certain transaction costs, the aggregate amount of outstanding liabilities, and a transaction fee to Xeno. In addition, each Shareholder will also receive one non-transferablecontingent value right (each, a “ CVR”) for each Common Share that will entitle the holder to receive a pro rata portion of potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, the CVR Agreement (as defined and further described below). The cash payable at Closing is currently estimated to be approximately $1.82 per Common Share, exclusive of payments received pursuant to the CVR.

The Company’s transaction committee comprised entirely of independent directors of the board of directors of the Company (the “ Board,” and such transaction committee, the “ Transaction Committee”) following receipt and review of the opinion of the Transaction Committee’s financial advisors, determined that the Arrangement (defined below) is fair to the Shareholders, and that the Arrangement is in the best interests of the Company.

The Board, after consultation with the Company’s management and legal advisors and, following the receipt and review of the unanimous recommendation from the Transaction Committee and the opinion of the Transaction Committee’s financial advisors, has unanimously approved the Transaction and determined that the Transaction is in the best interests of the Company and is fair to the Shareholders. The Board has unanimously resolved to recommend that the Shareholders vote in favor of the Transaction, subject to the terms and conditions contained in the Agreement.

The Transaction will be implemented by way